Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2025-12-25 @ 2:03 AM
NCT ID:
NCT00195260
Eligibility Criteria:
Inclusion Criteria:
* Advanced or recurrent solid malignancy confirmed histologically or cytologically for which no effective therapy is available.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.
* Measurable disease as outlined by the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
* Other inclusion applies.
Exclusion Criteria:
* Use of any systemic antitumor agents or any investigational agent within 28 days before the first dose of test article is administered.
* Prior exposure to SKI-606 or any other Src-kinase inhibitor, major surgery or radiotherapy within 14 days before the first dose of test article (recovery from previous surgery should be complete before day 1).
* Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth (Treated CNS metastases must be stable for \>= 2 weeks before day 1).
* Other exclusion applies.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00195260
Study Brief:
Protocol Section:
NCT00195260